Sonoma Pharmaceuticals In... (SNOA)
NASDAQ: SNOA
· Real-Time Price · USD
3.06
-0.37 (-10.79%)
At close: May 06, 2025, 3:59 PM
-10.79% (1D)
| Bid | 3.01 |
| Market Cap | 4.94M |
| Revenue (ttm) | 13.97M |
| Net Income (ttm) | -3.75M |
| EPS (ttm) | -2.26 |
| PE Ratio (ttm) | -1.35 |
| Forward PE | -1.89 |
| Analyst | n/a |
| Ask | 3.21 |
| Volume | 52,378 |
| Avg. Volume (20D) | 2,749,535 |
| Open | 3.24 |
| Previous Close | 3.43 |
| Day's Range | 3.04 - 3.24 |
| 52-Week Range | 1.75 - 9.40 |
| Beta | 1.67 |
About SNOA
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; ...
Sector Healthcare
IPO Date Jan 25, 2007
Employees 10
Stock Exchange NASDAQ
Ticker Symbol SNOA
Website https://www.sonomapharma.com
Next Earnings Release
Sonoma Pharmaceuticals Inc. is scheduled to release its earnings on Jun 16, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+4.95%
Sonoma Pharmaceuticals shares are trading higher a...
Unlock content with
Pro Subscription
1 month ago
+21.86%
Sonoma Pharmaceuticals shares are trading higher after the company announced it secured UK regulatory clearances for its key wound care and dermatology products.
2 months ago · accessnewswire.com
Sonoma Pharmaceuticals to Exhibit at 2025 American Academy of Dermatology Annual Meeting in OrlandoBOULDER, CO / ACCESS Newswire / February 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypoc...